Comparing the longer-term effectiveness of a single dose of the Pfizer-BioNTech and Oxford-AstraZeneca COVID-19 vaccines across the age spectrum

BACKGROUND: A single dose strategy may be adequate to confer population level immunity and protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, especially in low- and middle-income countries where vaccine supply remains limited. We compared the effectiveness of...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaura, Amit, Trickey, Adam, Shah, Anoop S V, Benedetto, Umberto, Glampson, Ben, Mulla, Abdulrahim, Mercuri, Luca, Gautama, Sanjay, Costelloe, Ceire E, Goodman, Ian, Redhead, Julian, Saravanakumar, Kavitha, Mayer, Erik, Mayet, Jamil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8918854/
https://www.ncbi.nlm.nih.gov/pubmed/35295900
http://dx.doi.org/10.1016/j.eclinm.2022.101344

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8918854/
https://www.ncbi.nlm.nih.gov/pubmed/35295900
http://dx.doi.org/10.1016/j.eclinm.2022.101344

Ejemplares similares